SG Americas Securities Boosts Twist Bioscience Holdings by 350%

Institutional investor significantly increases stake in synthetic biology company

Apr. 5, 2026 at 8:43am

Got story updates? Submit your updates here. ›

SG Americas Securities LLC, a major institutional investor, has increased its holdings in Twist Bioscience Corporation (NASDAQ: TWST) by 350.3% in the fourth quarter, according to a recent SEC filing. The firm now owns 76,484 shares of the company's stock, worth approximately $2.4 million.

Why it matters

Twist Bioscience is a leading synthetic biology company that has pioneered a proprietary DNA synthesis platform. The significant increase in SG Americas Securities' stake suggests strong institutional confidence in Twist's technology and growth potential within the rapidly evolving field of genomics and biotechnology.

The details

According to the filing, SG Americas Securities acquired an additional 59,500 shares of Twist Bioscience during the fourth quarter, bringing its total position to 76,484 shares. This represents a 350.3% increase from the previous quarter. The investment firm now owns 0.13% of Twist's outstanding shares.

  • SG Americas Securities filed the SEC disclosure on April 5, 2026.
  • The increased stake was reported for the fourth quarter of 2025.

The players

SG Americas Securities LLC

A major institutional investment firm that has significantly increased its stake in Twist Bioscience.

Twist Bioscience Corporation

A synthetic biology company that has developed a proprietary DNA synthesis platform and is a leader in the rapidly evolving genomics and biotechnology industry.

Got photos? Submit your photos here. ›

The takeaway

The substantial increase in SG Americas Securities' position in Twist Bioscience underscores the growing institutional interest and investment in innovative synthetic biology companies that are driving advancements in genomics, biotechnology, and life sciences.